Oppenheimer & Co’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Oppenheimer & Co’s Portfolio BTAL Stock Details BTAL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,828	Closed	-$310K	–	1560
2024 Q3	$310K	Buy	+15,828	New	+$315K	﹤0.01%	1212
2023 Q2	–	Sell	-19,527	Closed	-$398K	–	1418
2023 Q1	$398K	Sell	19,527 -16,392	-46%	-$330K	0.01%	1026
2022 Q4	$762K	Buy	+35,919	New	+$745K	0.02%	770
2020 Q4	–	Sell	-19,474	Closed	-$459K	–	1352
2020 Q3	$459K	Buy	19,474 +2,505	+15%	+$60K	0.01%	840
2020 Q2	$413K	Buy	+16,969	New	+$419K	0.01%	865

Other funds holding BTAL

TAF

Tredje AP-fonden Se-111 91 Stockholm, Sweden $18.3B AUM 27.14% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Oppenheimer & Co's BTAL Position: Q4 2024 in Review

Oppenheimer & Co sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2024, closing a stake of 15,828 shares — an estimated $310K sold.

Oppenheimer & Co first reported a position in BTAL in Q2 2020 and held it in 5 quarters. The position peaked at $762K in Q4 2022. 68 funds tracked by Wall St. Rank hold BTAL as of Q4 2024.

Oppenheimer & Co reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2024 after selling out during the quarter.
Oppenheimer & Co sold 15,828 AGF US Market Neutral Anti-Beta Fund shares in Q4 2024, an estimated $310K.
Oppenheimer & Co first reported a position in AGF US Market Neutral Anti-Beta Fund in Q2 2020 and held it in 5 quarters.
Oppenheimer & Co's AGF US Market Neutral Anti-Beta Fund position peaked at $762K in Q4 2022.
68 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2024.

Based on Oppenheimer & Co's 13F filing for Q4 2024, filed 5 Feb 2025.